Diagnostic imaging company Bracco announced that more than 6 million intravenous doses of VUEWAY (gadopiclenol) have been administered worldwide since its initial 2022 approval, following 2026 EU and U.S. pediatric extensions to term neonates and infants. The release also highlights the Max 3 injector and AiMIFY software, without disclosing product sales revenue.
Bracco Diagnostics, Bracco Delivers 6 Million VUEWAY (gadopiclenol) Injection Doses Worldwide as Its MRI Portfolio Continues to Evolve4 min read Data included
Everest Medicines announced on 20 November 2026 that the first patient was treated in China in the 244-patient Phase 2b ASCEND trial comparing VIS-101 against 2 mg aflibercept in wet age-related macular degeneration, ahead of a planned 2027 global Phase 3 program.
Everest Medicines, First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD4 min read Data included
Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.
Johnson & Johnson, Phase 4 STAR Study Results for TREMFYA in Axial Psoriatic Arthritis5 min read Data included
PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.
PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 20264 min read Data included
United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.
United Therapeutics Corporation, First Transplant in EXTEND Clinical Trial of UThymoKidney5 min read Data included
The World Health Organization's Global Accelerator for Paediatric Formulations Network published an update on 20 November 2026 reaffirming its 2025-2030 roadmap and 30 by '30 targets across 10 diseases, 10 medicines and 10 countries, alongside a new South-East Asia pilot report.
World Health Organization, GAP-f Partners Accelerate Action on World Children's Day4 min read Data included
UKHSA surveillance recorded 21,129 antibiotic-resistant bacteraemia cases in 2025, 16.8% above 2019, although the annual increase slowed to 3.2%. NHS antibiotic use fell over the period, showing that lower use alone has not reversed the reported resistance burden.
UK Health Security Agency, Over 400 antibiotic-resistant infections each week in 20254 min read Data included
A national Australian report found knee CT scans rose 83% and ultrasounds 26% over five years to 2023-24 among people aged 45 and older. Arthroscopy rates fell by half over a decade, while knee replacements rose 17%; the data describe service use, not proof that imaging caused surgery.
Australian Commission on Safety and Quality in Health Care, Atlas Focus Report: Osteoarthritis of the knee4 min read Data included
A five day course focused on keeping clinics operating through floods, cyclones and landslides. Earlier releases reported training cohorts of 38 in Temotu and 36 in Makira.
WHO media release on Guadalcanal health emergency training5 min read Data included
WHO reports a 59 out of 100 score across 40 countries, while two other WHO pages cite 37 and 38 countries. The public material does not explain the coverage differences.
WHO Africa report on health information systems4 min read Data included